Recommendations released to help the EU combat high drug prices
New briefing documents provide policy recommendations to help the EU tackle high medicines prices brought about by market monopolies.
List view / Grid view
New briefing documents provide policy recommendations to help the EU tackle high medicines prices brought about by market monopolies.
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
GlaxoSmithKline (GSK) has been given Chinese approval for its shingles vaccine.
Member countries of WHO have agreed to support pricing transparency for medicines, vaccines and other health products.
Global active pharmaceutical ingredients market set to surpass US$274.9 billion by 2026.
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
Regulatory reforms and harmonisation reported as key drivers of industry in China.
The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
The single-use bioprocessing systems market in Asia Pacific has witnessed an impressive rise and is expected to continue growing.
A coalition of 43 attorneys general allege generic drug manufacturers colluded, overcharging US states and consumers billions.
A new study has found that prices for brand-name prescription drugs averaged 3.2 to 4.1 times higher in the US compared with other countries.
Marketing authorisation has been recommended in the EU by an EMA committee for Sixmo (buprenorphine) as a substitution treatment for opioid dependence.
The US government has filed criminal charges against Rochester Drug Co-Operative (RDC), one of the largest pharmaceutical distribution companies in the US, and its former CEO Laurence Doud III and former Chief of Compliance Officer, William Pietruszewski.
With the UK bracing itself for a 'no-deal' Brexit or some other outcome that has not yet been determined, pharma experts discussed the potential effect of Brexit on the supply chain and how to best prepare for it against the upcoming deadline.